Vimarsana
Biggest News Aggregation in the World

Page 14 - Arthur Chen News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Arthur Chen. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Arthur Chen Today - Breaking & Trending Today

'China's Robinhood' Tries to Calm Investor Nerves as Shares Sink - Vimarsana News

'China's Robinhood' Tries to Calm Investor Nerves as Shares Sink

'China's Robinhood' Tries to Calm Investor Nerves as Shares Sink - Online broker Futu struggles in crosshairs of Beijing's regulatory pressure

Futu Holdings Limited (FUTU) Q3 2021 Earnings Call Transcript - Vimarsana News

Futu Holdings Limited (FUTU) Q3 2021 Earnings Call Transcript

FUTU earnings call for the period ending September 30, 2021.

Source: fool.com
Futu Holdings Limited (FUTU) Q3 2021 Earnings Call Transcript - Vimarsana News

Futu Holdings Limited (FUTU) Q3 2021 Earnings Call Transcript

FUTU earnings call for the period ending September 30, 2021.

Source: fool.com
5 Chinese Films To Watch This Cozy Autumn - Vimarsana News

5 Chinese Films To Watch This Cozy Autumn

The autumn season has officially dawned upon us. With the weather getting chillier, we just want to kick back at home and relax. While keeping warm and cozy at home, you may be in the mood to binge watch something. If dramas are too much of a time commitment, why not check out some Chinese

Source: soompi.com
COVID-19: Foundation questions Medigen vaccine - Vimarsana News

COVID-19: Foundation questions Medigen vaccine

The Chinese Nationalist Party (KMT)-affiliated National Policy Foundation yesterday questioned the safety and effectiveness of COVID-19 vaccine candidates from Medigen Vaccine Biologics Corp, citing a lack of phase 3 trials. Foundation deputy director Huang Hsin-hua (黃心華) made the remarks in an online news conference a day after Medigen unblinded data from its phase 2 trials. Although Medigen increased the sample pool of subjects in its phase 2 clinical tests in a bid to secure emergency use authorization, an expanded phase 2 is no substitute for phase 3 trials, Huang said. The lack of p...